Pharmaceutical treatments (Varenicline) Source: ERS Course 2015 Year: 2015
Pharmaceutical treatments (NRTs) Source: ERS Course 2015 Year: 2015
Bupropion hydrochloride (Zyban™) is effective and well tolerated as an aid to smoking cessation - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 11s Year: 2001
Pharmaceutical Treatment Source: Research Seminar 2007 - The limits to exercise in COPD: new insights from new methods Year: 2007
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Bupropion together with cognitive-conductual therapy (CBT) is an alternative for a long-term abstinence of smoking Source: Annual Congress 2013 –Smoking cessation for healthy and non-healthy smokers Year: 2013
LATE-BREAKING ABSTRACT: Single-dose safety, tolerability, PD & PK of AZD8999, a bi-functional muscarinic antagonist/β2-agonist (MABA), in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Cost effectiveness of inpatient initiated varenicline tartrate (VT) plus counselling compared to counselling alone: 2 year follow-up of the Smoking Termination Opportunity for inPatients (STOP) study Source: International Congress 2016 – Emerging issues in smoking cessation and tobacco products Year: 2016
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Prescription behaviour of short-acting ß2-agonists in Switzerland Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK) Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Treatment of tobacco addiction using the feeling-state addiction protocol (FSAP) of the eye movement desensitization and reprocessing (EMDR) treatment Source: Annual Congress 2013 –Smoking cessation for healthy and non-healthy smokers Year: 2013